Stay updated on Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial

Sign up to get notified when there's something new on the Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, representing the effect of combination therapy with pioglitazone plus dapagliflozin versus placebo on hospitalization for heart failure in patients with HFpEF, focusing on correcting myocardial metabolic abnormalities in subjects with T2DM and diastolic dysfunction.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:14.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for individuals diagnosed with type 2 diabetes and meeting certain health conditions. Previously, this section had no information provided.
    Difference
    14%
    Check dated 2024-05-22T21:29:18.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:15:27.000Z thumbnail image

Stay in the know with updates to Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dapagliflozin+Low-Dose Pioglitazone on HF Hospitalization Clinical Trial page.